Cargando…

P838: PEGCETACOPLAN RAPIDLY STABILIZES COMPLEMENT INHIBITOR NAÏVE PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA EXPERIENCING HEMOLYSIS WITH ACUTE HEMOGLOBIN DECREASES; PRINCE TRIAL POST HOC ANALYSIS

Detalles Bibliográficos
Autores principales:	Wong, R., Al-Adhami, M., Savage, J., Horneff, R., Yeh, M., Dumagay, T., Gomez-Almaguer, D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431010/ http://dx.doi.org/10.1097/01.HS9.0000846236.11666.3d

Ejemplares similares

Pegcetacoplan controls hemolysis in complement inhibitor–naive patients with paroxysmal nocturnal hemoglobinuria
por: Wong, Raymond Siu Ming, et al.
Publicado: (2023)

P833: CATEGORIZING HEMATOLOGICAL RESPONSE TO PEGCETACOPLAN IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: A POST HOC ANALYSIS OF THE PHASE 3 PRINCE STUDY DATA
por: Risitano, A., et al.
Publicado: (2022)

Inhibition of C3 with pegcetacoplan results in normalization of hemolysis markers in paroxysmal nocturnal hemoglobinuria
por: Wong, Raymond S. M., et al.
Publicado: (2022)

Safety and efficacy of pegcetacoplan in paroxysmal nocturnal hemoglobinuria
por: Wong, Raymond S.M.
Publicado: (2022)

P794: EVALUATION OF PEGCETACOPLAN IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS WITH APLASTIC ANEMIA IN THE PRINCE STUDY
por: Bogdanovic, Andrija, et al.
Publicado: (2023)

P786: THROMBOSIS AND MENINGOCOCCAL INFECTION RATES IN PEGCETACOPLAN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA IN THE CLINICAL TRIAL AND POST-MARKETING SETTINGS
por: Kelly, Richard, et al.
Publicado: (2023)

Pegcetacoplan ‐ a novel C3 inhibitor for paroxysmal nocturnal hemoglobinuria
por: Rehan, Syeda Tayyaba, et al.
Publicado: (2022)

Pegcetacoplan in paroxysmal nocturnal hemoglobinuria: A systematic review on efficacy and safety
por: Shah, Sangam, et al.
Publicado: (2022)

P839: PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATED WITH PEGCETACOPLAN SHOW IMPROVEMENTS IN D-DIMER NORMALIZATION AND DECREASE IN INCIDENCE OF THROMBOSIS
por: Weitz, I., et al.
Publicado: (2022)

C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab
por: de Castro, Carlos, et al.
Publicado: (2020)

PB2054: EXPOSURE-RESPONSE ANALYSES OF PEGCETACOPLAN IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
por: Ping, Haili, et al.
Publicado: (2023)

PB2053: POPULATION PHARMACOKINETICS OF PEGCETACOPLAN IN HEALTHY SUBJECTS AND PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
por: Ping, Haili, et al.
Publicado: (2023)

The cost–effectiveness of pegcetacoplan in complement treatment-naïve adults with paroxysmal nocturnal hemoglobinuria in the USA
por: Fishman, Jesse, et al.
Publicado: (2023)

Injection Site Reactions with Long-Term Pegcetacoplan Use in Patients with Paroxysmal Nocturnal Hemoglobinuria: A Brief Report
por: Sharma, Vivek, et al.
Publicado: (2023)

P828: NORMALIZATION OF HEMATOLOGIC AND HEALTH-RELATED QUALITY OF LIFE MARKERS IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATED WITH PEGCETACOPLAN AND BASELINE HEMOGLOBIN AT OR ABOVE 10 G/DL
por: Panse, J., et al.
Publicado: (2022)

Breakthrough Hemolysis Associated With COVID-19 Vaccination and Active COVID-19 Infection in a Patient With Paroxysmal Nocturnal Hemoglobinuria Maintained on Pegcetacoplan: A Case Report
por: Boshkos, Mitchell C, et al.
Publicado: (2023)

COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal hemoglobinuria
por: Gerber, Gloria F., et al.
Publicado: (2021)

Severe Hemolysis in a COVID-19 Patient with Paroxysmal Nocturnal Hemoglobinuria
por: Otieno, Steve Biko, et al.
Publicado: (2021)

Comparative Effectiveness of Pegcetacoplan Versus Ravulizumab and Eculizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: A Matching-Adjusted Indirect Comparison
por: Wong, Raymond, et al.
Publicado: (2023)

Pegcetacoplan: A Review in Paroxysmal Nocturnal Haemoglobinuria
por: Heo, Young-A
Publicado: (2022)

P840: A MATCHING-ADJUSTED INDIRECT COMPARISON OF THE EFFICACY OF PEGCETACOPLAN USING PRINCE TRIAL DATA VERSUS RAVULIZUMAB AND ECULIZUMAB IN COMPLEMENT-NAÏVE PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
por: Wong, R., et al.
Publicado: (2022)

Correction to: Comparative Effectiveness of Pegcetacoplan Versus Ravulizumab and Eculizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: A Matching-Adjusted Indirect Comparison
por: Wong, Raymond, et al.
Publicado: (2023)

P781: EVALUATION OF PEGCETACOPLAN TREATMENT SUCCESS IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WITH AND WITHOUT BONE MARROW FAILURE: A MOVE TOWARDS INDIVIDUALIZED PATIENT TREATMENT
por: Szer, Jeff, et al.
Publicado: (2023)

Thrombotic complications without evidence of hemolysis in paroxysmal nocturnal hemoglobinuria: is eculizumab indicated?
por: Bellido, M., et al.
Publicado: (2012)

The Effect of Respiratory Viral Infections on Breakthrough Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria
por: Lazana, Ioanna, et al.
Publicado: (2023)

Correction to: Pegcetacoplan: A Review in Paroxysmal Nocturnal Haemoglobinuria
por: Heo, Young-A.
Publicado: (2023)

PB2064: THE COMPLETE STUDY: A SINGLE ARM, MULTICENTER OBSERVATIONAL STUDY TO EVALUATE EFFECTIVENESS OF PEGCETACOPLAN UNDER REAL WORLD CONDITIONS IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
por: de Latour, Régis Peffault, et al.
Publicado: (2023)

P757: INCIDENCE RATES OF HEALTHCARE RESOURCE UTILIZATION AND HEMOGLOBIN LEVELS DURING OPERA: A REAL-WORLD STUDY OF PEGCETACOPLAN TREATMENT IN US ADULTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
por: Fishman, Jesse, et al.
Publicado: (2023)

Necrotizing Fasciitis in Paroxysmal Nocturnal Hemoglobinuria
por: Patir, Pusem, et al.
Publicado: (2015)

Evolutionary dynamics of paroxysmal nocturnal hemoglobinuria
por: Mon Père, Nathaniel, et al.
Publicado: (2018)

Renal Manifestations in Paroxysmal Nocturnal Hemoglobinuria
por: Ram, R., et al.
Publicado: (2017)

Insights Into the Emergence of Paroxysmal Nocturnal Hemoglobinuria
por: Colden, Melissa A., et al.
Publicado: (2022)

Management of paroxysmal nocturnal hemoglobinuria (PNH)
por: Luzzatto, Lucio
Publicado: (2022)

Paroxysmal Nocturnal Hemoglobinuria: Biology and Treatment
por: Bravo-Perez, Carlos, et al.
Publicado: (2023)

Early Mortality in Paroxysmal Nocturnal Hemoglobinuria
por: Sørensen, Anne Lykke, et al.
Publicado: (2023)

Preoperative administration of eculizumab to prevent surgery‐triggered hemolysis during cesarean section with paroxysmal nocturnal hemoglobinuria
por: Li, Dongping, et al.
Publicado: (2018)

Hemolysis induced by SARS-CoV-2 mRNA vaccination in patients with paroxysmal nocturnal hemoglobinuria
por: Kamura, Yuya, et al.
Publicado: (2022)

Pregnancy in Classical Paroxysmal Nocturnal Hemoglobinuria and Aplastic Anemia–Paroxysmal Nocturnal Hemoglobinuria: A High-Risk Constellation
por: Alashkar, Ferras, et al.
Publicado: (2020)

Changes in hemoglobin and clinical outcomes drive improvements in fatigue, quality of life, and physical function in patients with paroxysmal nocturnal hemoglobinuria: post hoc analyses from the phase III PEGASUS study
por: Cella, David, et al.
Publicado: (2022)

Successful pregnancy outcome in paroxysmal nocturnal hemoglobinuria (PNH) following escalated eculizumab dosing to control breakthrough hemolysis
por: Sharma, Ruby, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_09d3rnjuhkc3ndiu6smoeojunp